Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman Sells 3,982 Shares

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 3,982 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $26.61, for a total transaction of $105,961.02. Following the completion of the sale, the general counsel now directly owns 159,137 shares of the company’s stock, valued at approximately $4,234,635.57. This trade represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Phreesia Price Performance

PHR stock opened at $28.42 on Thursday. The firm has a market capitalization of $1.65 billion, a P/E ratio of -19.33 and a beta of 0.94. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $29.16. The company has a quick ratio of 1.77, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. The company has a fifty day simple moving average of $22.50 and a two-hundred day simple moving average of $22.53.

Phreesia (NYSE:PHR) last announced its earnings results on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.04. The business had revenue of $106.80 million for the quarter, compared to the consensus estimate of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The business’s revenue for the quarter was up 16.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.58) earnings per share. Analysts anticipate that Phreesia, Inc. will post -1.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

PHR has been the topic of a number of recent analyst reports. Truist Financial raised their price target on Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. KeyCorp boosted their price target on Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 price objective on shares of Phreesia in a report on Tuesday, December 10th. Robert W. Baird lowered their target price on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Finally, JMP Securities restated a “market outperform” rating and set a $30.00 target price on shares of Phreesia in a research report on Tuesday, December 10th. Eleven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $30.64.

Institutional Investors Weigh In On Phreesia

A number of institutional investors and hedge funds have recently modified their holdings of the business. International Assets Investment Management LLC grew its position in Phreesia by 2,179.7% in the 3rd quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock valued at $33,000 after acquiring an additional 1,395 shares during the last quarter. Lombard Odier Asset Management USA Corp purchased a new position in Phreesia in the 2nd quarter worth about $202,000. Point72 DIFC Ltd bought a new stake in Phreesia during the 2nd quarter valued at about $209,000. XTX Topco Ltd purchased a new stake in Phreesia in the 3rd quarter valued at about $247,000. Finally, Hsbc Holdings PLC bought a new position in Phreesia in the 2nd quarter worth about $301,000. 92.10% of the stock is owned by institutional investors.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.